# A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4

> **NCT01409135** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 34 (actual)

## Conditions studied

- Tumors
- Medical Oncology
- Neoplasms

## Interventions

- **DRUG:** AGS-22M6E
- **DRUG:** ASG-22CE

## Key facts

- **NCT ID:** NCT01409135
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-11
- **Primary completion:** 2015-04-27
- **Final completion:** 2015-04-27
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-03-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01409135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01409135, "A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01409135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*